Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 13, 2025
Glycolysis Inhibition Restores Immune Sensitivity in GSNOR-Deficient Colorectal CancerAna Mantrana, María Teresa Sánchez-Montero, Carmen Navarrete-Sirvent, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2018
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD databaseMohamed E Salem, Jun Yin, Benjamin A Weinberg, et al.
The Oncologist|November 16, 2024
Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 studyPilar García-Alfonso, Paula Jimenez-Fonseca, Javier Soto-Alsar, et al.
British Journal of Cancer|December 23, 2021
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trialElena Élez, María Auxiliadora Gómez-España, Cristina Grávalos, et al.
The Oncologist|January 12, 2012
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD studyEduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, et al.
ESMO Open|November 5, 2020
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trialEnrique Aranda, Jose Maria Viéitez, Auxiliadora Gómez-España, et al.
JAMA Network Open|October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT TrialBenoist Chibaudel, Julie Henriques, Manel Rakez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 20, 2024
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) studyManuel Valladares-Ayerbes, Maria José Safont, Encarnación González Flores, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2017
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative GroupAntonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, et al.
BMC Cancer|February 15, 2018
HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinomaA Arjona-Sánchez, P Barrios, E Boldo-Roda, et al.
Pageof 15